Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT05934526 is registered in ClinicalTrials.gov with GB002, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- GB002, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 28, 2023
- Completion date
- December 22, 2025
- Enrollment
- 390 (actual)
- Sites
- 166
Conditions
As the registry lists them; a condition with its own page is linked.